China Pharma Holdings Inc. (CPHI)
$0.90
$0.14
(18.30%)
As on 26-Aug-2026 16:08EDT
Market cap
$46 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
1.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
37.31
-
EV/EBITDA
-225.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.9
-
Face value
--
-
Shares outstanding
43,022,002
10 Years Aggregate
CFO
$12.12 Mln
EBITDA
$-49.47 Mln
Net Profit
$-122.09 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
China Pharma Holdings (CPHI)
| -25.7 | -- | 18.3 | -36.7 | -56.6 | -69.9 | -38.9 |
|
BSE Sensex*
| -8.8 | 1.5 | 1.6 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
China Pharma Holdings (CPHI)
| -48.0 | -60.9 | -87.5 | -79.2 | 7.7 | 88.3 | -8.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
China Pharma Holdings (CPHI)
|
0.9 | 45.6 | 3.9 | -4.5 | -81.2 | -15.2 | -- | 1.3 |
| 18.0 | 6,238.0 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 188.9 | |
| 207.2 | 10,883.2 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 130.9 | |
| 79.4 | 15,932.7 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 119.8 | 13,215.0 | 830.8 | 54.9 | 3.2 | 8.1 | 271.7 | 18.7 | |
| 12.2 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 25.1 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 287.9 | 5,707.4 | 290.5 | 197.2 | 82.5 | 19.9 | 29.6 | 5.9 | |
| 71.4 | 6,142.1 | 450.9 | 138.6 | 39.1 | 115.6 | 49 | 31.5 | |
| 150.1 | 9,129.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 20.5 |
Shareholding Pattern
View DetailsAbout China Pharma Holdings (CPHI)
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and... cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China. Read more
-
President, CEO, Chairman & Interim CFO
Ms. Zhilin Li
-
President, CEO, Chairman & Interim CFO
Ms. Zhilin Li
-
Headquarters
Haikou
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for China Pharma Holdings (CPHI)
What is the current share price of China Pharma Holdings Inc (CPHI) Today?
The share price of China Pharma Holdings Inc (CPHI) is $0.90 (NYSE) as of 26-Aug-2026 16:08 EDT. China Pharma Holdings Inc (CPHI) has given a return of -56.6% in the last 3 years.
What is the current PB & PE ratio of China Pharma Holdings Inc (CPHI)?
Since, TTM earnings of China Pharma Holdings Inc (CPHI) is negative, P/E ratio is not available.
The P/B ratio of China Pharma Holdings Inc (CPHI) is 1.28 times as on 21-Aug-2026, a 83 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-5.89 |
0.83 |
2024 |
-0.23 |
0.14 |
2023 |
-0.41 |
0.17 |
2022 |
-0.16 |
0.14 |
2021 |
-0.68 |
0.38 |
What is the 52 Week High and Low of China Pharma Holdings Inc (CPHI)?
The 52-week high and low of China Pharma Holdings Inc (CPHI) are Rs 2.03 and Rs 0.38 as of 27-Aug-2026.
What is the market cap of China Pharma Holdings Inc (CPHI)?
China Pharma Holdings Inc (CPHI) has a market capitalisation of $ 46 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in China Pharma Holdings Inc (CPHI)?
Before investing in China Pharma Holdings Inc (CPHI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.